Abstract:Currently, there is no specific treatment for acute lung injury (ALI) in clinical practice. In order to efficiently and accurately treat ALI, the advantages of cationic carriers were combined to accelerate the cell uptake. Polycaprolactone-polyethylene glycol carrier (PCL-PEG-COOH, PPC) with good biocompatibility, polycaprolactone-polyethylmethacrylate cationic carrier (PCL-PDMAEMA, PCD), and polycaprolactone-polyethylene glycol carrier connected with high-affinity targeting peptide (Esbp) targeting inflammatory endothelial cells (PCL-PEG-Esbp, PPE) were used to construct the high-molecular polymer micelles (PCD/PPC/PPE). The particle size of the prepared DEX-loaded micelles was 130 ± 4.41 nm, and the Zeta potential was 28.3 ± 0.76 mV. The CMC value of the prepared polymer micelles was 0.643 μg/mL, and it was not easy to depolymerize in the blood circulation. Only about 40% DXM was released from the drug-loaded polymer micelles after 12 h compared with free DXM, indicating that the micelle material had a certain sustained-release performance in vitro release experiments. The safe concentration range of polymer was determined by biocompatibility test. It was recommended that the concentration of polymer micelles should not exceed 0.40 mg/mL to obtain a good compatibility in organisms. The results of cytotoxicity measurement showed that when the content of PCD increased to 50%, the concentration of blank micelles should not exceed 500 μg/mL and the concentration of DXM-loaded micelles should not be higher than 100 μg/mL. It was proved in the cell uptake experiment that the cation carrier of the micelles accelerated the cell uptake. The targeting ability of the targeted micelle group was higher compared with the non-targeted micelle group ( P < 0.01, **). Meanwhile, the targeting ability of the non-targeted micelle group was higher compared with the free group ( P < 0.001, ***). The targeting ability of the non-targeted micelle group was about 2.30 times and the targeted micelle group was about 3.16 times larger than that of the free group. It was also proved in the in vivo targeting experiments that the targeted micelles had a good targeting ability. The results of in vivo imaging of mice showed that the DXM of the micelle group gathered more in the lungs, and the micelle group had a better targeting ability compared with the free DID group. The order of lung targeting intensity was targeted micelles > non-targeted micelles >> free DID group. The targeting ability of polypeptide Esbp to ALI was confirmed. In conclusion, the prepared PCD/PPC/PPE polymer micelles had obvious in vitro and in vivo targeting ability and good biocompatibility. They could be used as a new targeted delivery system for the treatment of ALI in the future.

E-Selectin-Binding Peptide–Modified Bovine Serum Albumin Nanoparticles for the Treatment of Acute Lung Injury

Compound Edaravone Alleviates Lipopolysaccharide (Lps)-Induced Acute Lung Injury in Mice.

ICAM-1 targeted and ROS-responsive nanoparticles for the treatment of acute lung injury

Ph-Responsive Nanoparticles Targeted to Lungs for Improved Therapy of Acute Lung Inflammation/Injury

Engineering of targeting antioxidant polypeptide nanopolyplexes for the treatment of acute lung injury

Pulmonary delivery of bioadhesive nanoparticles for ALI improvement and ARDS prevention with a single-dose administration

Scavenger receptor A-mediated nanoparticles target M1 macrophages for acute liver injury

Combined Delivery of Angiopoietin-1 Gene and Simvastatin Mediated by Anti-Intercellular Adhesion Molecule-1 Antibody-Conjugated Ternary Nanoparticles for Acute Lung Injury Therapy.

Self-Sulfhydrated, Nitro-Fixed Albumin Nanoparticles as a Potent Therapeutic Agent for the Treatment of Acute Liver Injury

Redox-sensitive disulfide-bridged self-assembled nanoparticles of dexamethasone with high drug loading for acute lung injury therapy

Targeted-lung delivery of bardoxolone methyl using PECAM-1 antibody-conjugated nanostructure lipid carriers for the treatment of lung inflammation

Surfactant Protein-a Nanobody-Conjugated Liposomes Loaded with Methylprednisolone Increase Lung-Targeting Specificity and Therapeutic Effect for Acute Lung Injury.

Baicalin Liposome Alleviates Lipopolysaccharide-Induced Acute Lung Injury in Mice Via Inhibiting TLR4/JNK/ERK/NF-κB Pathway

Baicalin Liposome Alleviates Lipopolysaccharide-Induced Acute Lung Injury in Mice via Inhibiting TLR4/JNK/ERK/NF- κ B Pathway

Anti-ICAM-1 antibody-modified nanostructured lipid carriers: a pulmonary vascular endothelium-targeted device for acute lung injury therapy

Targeting Delivery of Simvastatin Using ICAM-1 Antibody-Conjugated Nanostructured Lipid Carriers for Acute Lung Injury Therapy

Combined Computational and Experimental Studies of Molecular Interactions of Albuterol Sulfate with Bovine Serum Albumin for Pulmonary Drug Nanoparticles.

Therapeutic effect of pH-Responsive dexamethasone prodrug nanoparticles on acute lung injury

Physiologically based pharmacokinetic model for predicting the biodistribution of albumin nanoparticles after induction and recovery from acute lung injury

Construction of Inflammatory Directed Polymer Micelles and Its Application in Acute Lung Injury

INTRAVENOUS DELIVERY OF BONE MARROW-DERIVED ENDOTHELIAL PROGENITOR CELLS IMPROVES SURVIVAL AND ATTENUATES LIPOPOLYSACCHARIDE-INDUCED LUNG INJURY IN RATS